{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-006511","form_type":"8-K","ticker":"IMDX","cik":"0001642380","company_name":"Insight Molecular Diagnostics Inc.","filed_at":"2023-03-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.968217+00:00","generated_at":"2026-06-18T15:20:40.089458+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Oncocyte appoints Joshua Riggs as permanent CEO, President, and Board member","bullets":["Joshua Riggs appointed CEO effective Feb 24, 2023; also named President and joined Board on Feb 28.","Riggs served as interim CEO since Dec 2022, leading restructuring and cost reduction initiatives.","Board unanimously supports Riggs' appointment; Chair Andy Arno cites rapid spend reduction and strategic refocus.","Riggs previously held roles as General Manager, Transplant and Senior Director of Business Development at Oncocyte.","Company continues focus on precision diagnostics: DetermaIO, VitaGraft, and pipeline test DetermaCNI."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-006511","json":"https://secwatch.observer/filing/0001493152-23-006511.json","markdown":"https://secwatch.observer/filing/0001493152-23-006511.md","text":"https://secwatch.observer/filing/0001493152-23-006511.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1642380/000149315223006511/0001493152-23-006511-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1642380/000149315223006511/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T15:20:40.089458+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2e55d34fab","claim":"Joshua Riggs was appointed as Chief Executive Officer at Insight Molecular Diagnostics Inc..","evidence_excerpt":"Effective February 24, 2023, the Board of Directors of Oncocyte Corporation (“Oncocyte” or the “Company”) appointed Joshua Riggs as Chief Executive Officer of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1642380/000149315223006511/0001493152-23-006511-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"f730a6a559","claim":"Joshua Riggs was appointed as Director at Insight Molecular Diagnostics Inc..","evidence_excerpt":"Mr. Riggs has also been appointed President and joined the Company’s Board of Directors effective February 28, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1642380/000149315223006511/0001493152-23-006511-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"fa1a712016","claim":"Joshua Riggs was appointed as President at Insight Molecular Diagnostics Inc..","evidence_excerpt":"Mr. Riggs has also been appointed President and joined the Company’s Board of Directors effective February 28, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1642380/000149315223006511/0001493152-23-006511-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"President"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}